Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs

Increasingly Crowded Field

two new PD-L1 filing in China
Chinese biopharma companies' craving for PD-1/L1 approvals still growing • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

More from Focus On Asia